These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 9211018

  • 1. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
    de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A.
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
    [Abstract] [Full Text] [Related]

  • 2. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A.
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [Abstract] [Full Text] [Related]

  • 3. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire U, Hamsten A.
    J Am Coll Cardiol; 1998 Nov 15; 32(6):1648-56. PubMed ID: 9822092
    [Abstract] [Full Text] [Related]

  • 4. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U.
    Lancet; 1996 Mar 30; 347(9005):849-53. PubMed ID: 8622389
    [Abstract] [Full Text] [Related]

  • 5. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 30; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 6. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
    Ericsson CG.
    Eur Heart J; 1998 Jul 30; 19 Suppl H():H37-41. PubMed ID: 9717064
    [Abstract] [Full Text] [Related]

  • 7. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
    Ruotolo G, Båvenholm P, Brismar K, Eféndic S, Ericsson CG, de Faire U, Nilsson J, Hamsten A.
    J Am Coll Cardiol; 2000 Mar 01; 35(3):647-54. PubMed ID: 10716467
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG, Paterson JR.
    QJM; 2000 Sep 01; 93(9):567-74. PubMed ID: 10984551
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC, Duriez P.
    Drugs Today (Barc); 2006 Jan 01; 42(1):39-64. PubMed ID: 16511610
    [Abstract] [Full Text] [Related]

  • 16. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH.
    Circulation; 1994 Jul 01; 90(1):42-9. PubMed ID: 8026027
    [Abstract] [Full Text] [Related]

  • 17. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE.
    JAMA; 2007 Feb 07; 297(5):499-508. PubMed ID: 17284700
    [Abstract] [Full Text] [Related]

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 07; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
    Krakoff J, Vela BS, Brinton EA.
    Curr Cardiol Rep; 2000 Sep 07; 2(5):452-8. PubMed ID: 10980914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.